This phase Ib/II trial studies the side effects and best dose of venetoclax and how well it works when given together with ivosidenib with or without azacitidine, in treating patients with IDH1-mutated hematologic malignancies. Venetoclax and ivosidenib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ivosidenib and venetoclax with azacitidine may work better in treating patients with hematologic malignancies compared to ivosidenib and venetoclax alone.
Est. Enrollment: 30 participants
Study Start Date: Mar 19, 2018
Study Completion Date: Sep 30, 2021
Age: 18+ years
Gender: All
Contact Us
A member of our team would love to assist you.
How Clinical Trials Work (800) 930-5159 Email usSubscribe to the weekly "HealthTree Community for AML Newsletter" for AML news, life with AML stories, AML clinical trials, AML 101 articles and events with AML experts.
Terms of Use and Privacy Policy Newsroom About Donations Find an AML Specialist Newsletter Learn Connect
Copyright © 2022 HealthTree Foundation. All Rights Reserved.
The HealthTree Foundation / HealthTree for AML is a qualified 501(c)(3) tax-exempt organization. Tax ID 45-5354811